⌘K
t
Solvonis Therapeutics plc announced on 23 June 2025 that the U.S. Patent and Trademark Office (USPTO) allowed patent application U.S. No. 18/838,986. This application protects compounds within the Company's AI-enabled CNS discovery programme and is expected to confer U.S. exclusivity through to at least 2043.
| Date | 23 Jun 2025 |
| Time | 07:00:08 |
| Category | Corporate updates |
| ID | 8613N |
("Solvonis" or the "Company")
Allowance of U.S. patent covering AI-supported CNS discovery programme compounds
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is pleased to announce that the U.S. Patent and Trademark Office (the "USPTO") has allowed a key patent application protecting compounds within the Company's AI-enabled CNS discovery programme.
The application-U.S. No. 18/838,986, titled "Bridged Ring Compounds and Their Therapeutic Use as CNS Agents"-received a first-action allowance with no objections or rejections. The claims cover composition of matter and methods of use for a family of novel morpholine-class compounds, originally developed by Awakn Life Sciences Corp. and now central to Solvonis' Central Nervous System ("CNS") library.
An "allowance" confirms that a patent will be granted, subject only to final administrative steps.
The CNS library, which includes multiple chemically distinct, preclinically validated series, underpins Solvonis' AI-supported drug discovery platform. The patent adds meaningful protection across novel CNS chemical space, especially in depression, stimulant use disorder and other neuropsychiatric conditions.
The patent, expected to be granted in the coming months, will confer U.S. exclusivity through to at least 2043, reinforcing the long-term value of Solvonis' early-stage pipeline.
Professor David Nutt, Chief Scientific Officer of Solvonis, commented: "This patent strengthens the foundation of our discovery platform and provides long-term protection for a chemically distinct series of CNS-active compounds already integrated into our AI-supported programme. The favourable examination outcome reflects the novelty and robustness of the underlying chemistry, which has now been further validated through translational screening and computational analyses."
Anthony Tennyson, Chief Executive Officer of Solvonis, added: "We are delighted by this outcome, which validates the early-stage innovation acquired through Awakn and enhances the strategic value of our AI-enabled platform. This grant provides additional confidence as we advance our discovery pipeline targeting major unmet needs in neuropsychiatry."
Enquiries:
Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com
Allenby Capital Limited (Financial Adviser and Joint Broker)
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)
+44 (0) 20 3328 5656
Singer Capital Markets (Joint Broker)
Phil Davies
+44 (0) 20 7496 3000
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.
The Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD programme leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.
In addition, Solvonis is advancing an AI-supported discovery platform built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders. This initiative expands the Company's R&D pipeline into earlier-stage innovation while maintaining strategic focus on comorbid and underserved neuropsychiatric conditions.
With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.